Мультидисциплинарный подход в лечении больных с метастазами меланомы без выявленного первичного очага

The purpose of the study was to evaluate the method of combined modality treatment of patients with metastases of melanoma without detectable primary tumor. Metastases of melanoma of unknown primary origin were diagnosed in 21 (6 %) of 346 patients. Of them, 16 patients had metastases in lymph nodes, 4 in soft tissues and 1 in bones. To choose the treatment method, the general health status of the patient, location of metastases and the extent of tumor involvement were considered. The combined modality treatment of patients with metastases of melanoma with unknown primary site had allowed 10 patients to survive more than 3 years with no evidence of disease progression. The complete response was achieved in 10 (47,6 %) patients, partial response in 8 (38,1 %) patients and disease progression in 3 (14,3 %) patients. The 5-year survival rate was 46,1 ± 12,0 % and the median follow-up time was 52,0 ± 11,2 months.Цель – разработка методики комбинированного лечения больных с метастазами меланомы без выявленного первичного очага с помощью современной лучевой и лекарственной терапии. Материал: метастазы меланомы без ВПО были диагностированы у 21 (6 %) из 346 больных. В лимфатические узлы – у 16, в мягкие ткани – у 4, в кости – у 1 больного. При выборе методики лечения учитывались общее состояние больного, локализации метастазов, распространенность опухолевого процесса, предполагаемая локализация первичного очага. Комбинированное лечение больных с метастазами меланомы без ВПО позволило 10 больным прожить более 3 лет без признаков прогрессирования заболевания. При этом полный эффект достигнут у 10 (47,6 %), частич- ный – у 8 (38,1 %), прогрессирование наблюдалось у 3 (14,3 %). Пятилетняя выживаемость составила 46,1 ± 12,0 %, медиана наблюдения –52,0 ± 11,2 мес

Системная фотодинамическая терапия с фотосенсибилизатором фотолон в лечении онкологических больных с регионарными и отдаленными метастазами

 The results of photodynamic therapy (PDT) in 76 patients with tumors of different sites and with regional or distant metastases are represented. Sixty three patients were under combined or multimodal therapy, 13 patients had systemic PDT as monotherapy. The technique of PDT was as follows: the solution of photosensitizer photolon was administered intravenously at dose of 0.8–1.4 mg/ kg body weight. Laser blood irradiation was performed simultaneously (wavelength of 662 nm, output power of 20 mW, irradiation time of 50 min). Stabilization of the disease defined as the absence of new tumor foci was observed in 55% of treated patients: among them in 47% of patients with disseminated melanoma during 6–10 months after treatment, in 65% patients with breast cancer – for 3–6 years after treatment, and also in 100% of patients with cancer of other sites (colorectal, pancreatic, cervical, ovarian, lung and stomach cancer, retroperitoneal neuroblastoma) – for 10–12 months after treatment. According to ultrasound data the shrinkage of most of metastases up to its complete disappearance was observed. The authors consider that effects of systemic PDT are due to decrease of circulating tumor cells in blood and also due to beneficial impact of this modal of treatment on immune status of cancer patient. Intravenous PDT was shown to improve treatment results and quality of life in patients with metastases of malignant tumors. The approved technique is of considerable interest and requires further investigation of its efficiency including its combination with methods of combined and multimodal treatment. Приведены результаты применения фотодинамической терапии (ФДТ) у 76 пациентов с опухолями различной локализации и наличием регионарных или отдаленных метастазов. Шестьдесят три пациента находились в процессе комбинированного или комплексного лечения, 13 пациентам системная ФДТ проводилась как монотерапия. Методика проведения ФДТ заключалась в следующем: внутривенно вводили раствор фотосенсибилизатора фотолон в дозе 0,8–1,4 мг/кг массы тела. Одновременно проводили лазерное облучение крови больного (длина волны 662 нм, мощность лазера на выходе 20 мВт, время облучения 50 мин). Стабилизация процесса в виде отсутствия новых очагов опухоли наблюдалась у 55% пролеченных пациентов: в том числе у 47% больных с диссеминированной меланомой в течение 6–10 мес. после лечения, у 65% больных раком молочной железы – в течение 3–6 лет после лечения, а также у 100% больных с онкологической патологией другой локализации (рак прямой и ободочной кишки, поджелудочной железы, шейки матки, яичников, легкого и желудка, нейробластома забрюшинного пространства) – в течение 10–12 мес. после лечения. По данным УЗИ, отмечено уменьшение размеров большей части метастатических очагов вплоть до их полного исчезновения. Авторы считают, что реализация эффектов системной ФДТ происходит за счет уменьшения циркулирующих в крови опухолевых клеток, а также вследствие положительного влияния данного вида лечения на иммунный статус онкологических больных. Показано, что применение внутривенной ФДТ позволяет улучшить результаты лечения и качество жизни больных с метастазами злокачественных новообразований. Апробированная методика представляет значительный интерес, что требует дальнейшего изучения ее эффективности, в том числе, в сочетании с методами комбинированного и комплексного лечения.

MULTIDISCIPLINARY APPROACH TO THE TREATMENT OF PATIENTS WITH METASTASES OF MELANOMA WITHOUT DETECTABLE PRIMARY TUMOR

The purpose of the study was to evaluate the method of combined modality treatment of patients with metastases of melanoma without detectable primary tumor. Metastases of melanoma of unknown primary origin were diagnosed in 21 (6 %) of 346 patients. Of them, 16 patients had metastases in lymph nodes, 4 in soft tissues and 1 in bones. To choose the treatment method, the general health status of the patient, location of metastases and the extent of tumor involvement were considered. The combined modality treatment of patients with metastases of melanoma with unknown primary site had allowed 10 patients to survive more than 3 years with no evidence of disease progression. The complete response was achieved in 10 (47,6 %) patients, partial response in 8 (38,1 %) patients and disease progression in 3 (14,3 %) patients. The 5-year survival rate was 46,1 ± 12,0 % and the median follow-up time was 52,0 ± 11,2 months

Systemic photodynamic therapy with photosensitizer photolon in the treatment of cancer patients with regional and distant metastases

 The results of photodynamic therapy (PDT) in 76 patients with tumors of different sites and with regional or distant metastases are represented. Sixty three patients were under combined or multimodal therapy, 13 patients had systemic PDT as monotherapy. The technique of PDT was as follows: the solution of photosensitizer photolon was administered intravenously at dose of 0.8–1.4 mg/ kg body weight. Laser blood irradiation was performed simultaneously (wavelength of 662 nm, output power of 20 mW, irradiation time of 50 min). Stabilization of the disease defined as the absence of new tumor foci was observed in 55% of treated patients: among them in 47% of patients with disseminated melanoma during 6–10 months after treatment, in 65% patients with breast cancer – for 3–6 years after treatment, and also in 100% of patients with cancer of other sites (colorectal, pancreatic, cervical, ovarian, lung and stomach cancer, retroperitoneal neuroblastoma) – for 10–12 months after treatment. According to ultrasound data the shrinkage of most of metastases up to its complete disappearance was observed. The authors consider that effects of systemic PDT are due to decrease of circulating tumor cells in blood and also due to beneficial impact of this modal of treatment on immune status of cancer patient. Intravenous PDT was shown to improve treatment results and quality of life in patients with metastases of malignant tumors. The approved technique is of considerable interest and requires further investigation of its efficiency including its combination with methods of combined and multimodal treatment. </p